Related Experiment Video

Updated: Apr 22, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.8K

Bio-artificial heart as ultimate treatment of end-stage heart failure

Francis E Smit1, Pascal M Dohmen2

  • 1Department of Cardiothoracic Surgery, University of the Free State, Bloemfontein, South Africa.

Medical Science Monitor Basic Research
|October 17, 2014
PubMed

Insights

Tissue engineering offers a promising solution for end-stage heart failure, potentially creating a bio-artificial heart from decellularized matrices and patient cells. This approach could overcome organ donor limitations for heart transplantation.

Area of Science:

  • Biomedical Engineering
  • Regenerative Medicine
  • Cardiovascular Research

Background:

  • End-stage heart failure presents a significant global health challenge, with limited treatment options.
  • Current therapies include optimizing medical management, mechanical support systems, and heart transplantation.
  • Heart transplantation, while effective, is severely limited by a critical shortage of donor organs.

Purpose of the Study:

  • To explore tissue engineering as a novel strategy to address the limitations of current end-stage heart failure treatments.
  • To investigate the potential of creating a bio-artificial heart using decellularized extracellular matrix and autologous cells.

Main Methods:

  • Utilizing a decellularized extracellular matrix derived from biological sources.
  • Seeding the matrix with in vitro proliferated autologous cardiovascular cells.
  • Evaluating the regenerative, remodeling, and growth potential of the engineered construct.

Main Results:

  • Initial experimental studies show promising outcomes for bio-artificial heart development.
  • The approach aims to provide a readily available alternative to donor organs.
  • Challenges remain in translating experimental success to clinical application.

Conclusions:

  • Tissue engineering holds significant potential for regenerating and replacing damaged heart tissue.
  • The development of a bio-artificial heart could revolutionize treatment for end-stage heart failure.
  • Further research and development are necessary to overcome existing challenges and enable clinical availability.

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

8.9K
Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

28.4K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
624
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
606
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
742
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
766
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
696